Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine

References

• Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50(suppl 2):S37–44. doi:10.1086/648963.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Chapter 14: meningococcal disease. Public Health Foundation; [accessed 2020 Jan 28] https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/mening.pdf.
   Google Scholar
• MacNeil J, Cohn A. Chapter 8: meningococcal disease. Manual for the surveillance of vaccine-preventable diseases. 5th ed. Atlanta (GA): Centers for Disease Control and Prevention; 2017.
   Google Scholar
• Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echaniz-Aviles G, Findlow J, Head C, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313–28. doi:10.1080/14760584.2017.1258308.
   PubMed Web of Science ®Google Scholar
• Nimenrix®: EPAR - product information. Summary of product characteristics. Sandwich (UK): Pfizer Ltd; 2019.
   Google Scholar
• Mencevax® ACWY (meningococcal ACWY vaccine). Full prescribing information. Rixensart (Belgium): GlaxoSmithKline Biologicals; 2015.
   Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meer HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep; [accessed 2020 Feb 3] https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm.
   Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):e20162193. doi:10.1542/peds.2016-2193.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines. Pediatr Infect Dis J. 2015;34(12):e298–307. doi:10.1097/INF.0000000000000897.
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159(10):907–13. doi:10.1001/archpedi.159.10.907.
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Van der Wielen M, Reda M, Medlej F, Tabet C, Boutriau D, Sumbul A, Anis S, Miller JM. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis. 2012;16(8):e608–15. doi:10.1016/j.ijid.2012.04.006.
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang LM, Dubey A, Jain H, Bavdekar A, Lin TY, Bianco V, Baine Y, Miller JM. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin. 2011;7(2):239–47. doi:10.4161/hv.7.2.14068.
   PubMed Web of Science ®Google Scholar
• Quiambao BP, Jain H, Bavdekar A, Dubey AP, Kolhe D, Bianco V, Van der Wielen M, Miller JM. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents. Hum Vaccin Immunother. 2016;12(8):2162–68. doi:10.1080/21645515.2016.1163455.
   PubMed Web of Science ®Google Scholar
• Quiambao BP, Bavdekar A, Dubey AP, Jain H, Kolhe D, Bianco V, Miller JM, Van der Wielen M. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents. Hum Vaccin Immunother. 2017;13(3):636–44. doi:10.1080/21645515.2016.1248009.
   PubMed Web of Science ®Google Scholar
• Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccin Immunother. 2016;12(5):1300–10. doi:10.1080/21645515.2015.1136040.
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J. 2015;34(11):1236–43. doi:10.1097/INF.0000000000000866.
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J Pediatr. 2014;164(6):1409–1415.e1404. doi:10.1016/j.jpeds.2014.02.025.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis. 2013;17(3):e173–76. doi:10.1016/j.ijid.2012.10.001.
   PubMed Web of Science ®Google Scholar
• Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. 2013;32(4):e170–77. doi:10.1097/INF.0b013e318279ac38.
   PubMed Web of Science ®Google Scholar
• Peyrani P, Webber C, Van Der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL. Long-term antibody persistence after primary vaccination with MenACWY-TT and immunogenicity of a booster dose in individuals aged 11–55 years. Paper presented at: 37th Annual Meeting of the European Society of Paediatric Infectious Diseases; 2019 May 6–11; Ljubljana (Slovenia).
   Google Scholar
• National Center for Immunization and Respiratory Diseases Office of Infectious Diseases. Enhanced meningococcal disease surveillance report, 2017 (CS283195). Atlanta (GA): Centers for Disease Control and Prevention; 2017.
   Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61. doi:10.1016/S1473-3099(10)70251-6.
   PubMed Web of Science ®Google Scholar